[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 265,732,560
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 14,315 M
  • EBITDA $ 20,048 M
  • 60-Month Beta 0.24
  • Price/Sales 4.58
  • Price/Cash Flow 13.40
  • Price/Book 5.34

Options Overview Details

View History
  • Implied Volatility 27.49% (+0.76%)
  • Historical Volatility 37.00%
  • IV Percentile 55%
  • IV Rank 54.19%
  • IV High 34.22% on 02/05/26
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 20) 7.40 (4.36%)
  • Put/Call Vol Ratio 0.57
  • Today's Volume 861
  • Volume Avg (30-Day) 2,136
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 69,691
  • Open Int (30-Day) 70,104
  • Expected Range 162.25 to 177.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.64
  • Number of Estimates 3
  • High Estimate $2.69
  • Low Estimate $2.60
  • Prior Year $2.38
  • Growth Rate Est. (year over year) +10.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.06 +3.40%
on 07/20/26
196.41 -13.63%
on 07/02/26
-19.98 (-10.54%)
since 06/30/26
3-Month
164.06 +3.40%
on 07/20/26
196.41 -13.63%
on 07/02/26
-17.73 (-9.46%)
since 04/30/26
52-Week
145.79 +16.36%
on 09/25/25
212.71 -20.25%
on 02/18/26
+16.46 (+10.75%)
since 07/30/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised...

AZN : 169.64 (-0.99%)
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01...

AZN : 169.64 (-0.99%)
AZN.LN : 12,632.000 (-0.69%)
AstraZeneca results: H1 and Q2 2026

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030

AZN : 169.64 (-0.99%)
AZN.LN : 12,632.000 (-0.69%)
FOMC Out Next Week with Interest Rate Decision

Monday U.S. Economic Lookahead Durable-goods orders (June) Featured Earnings AstraZeneca ...

KLAC : 182.82 (+1.38%)
META : 556.71 (+3.28%)
AAPL : 308.91 (-7.35%)
KO : 87.59 (-1.02%)
CVX : 196.83 (+2.35%)
WELL : 234.44 (-0.51%)
ABBV : 250.94 (-2.51%)
MSFT : 464.72 (+3.02%)
MA : 573.10 (-0.74%)
AZN : 169.64 (-0.99%)
V : 366.13 (-0.04%)
XOM : 155.44 (-0.97%)
AstraZeneca's Monday Morning Call Will Reveal Whether Anyone Still Believes the Margin Math

Barchart Research What to Expect from AZN Earnings AZN Generated July 24, 2026 Current Price $169.26 EPS Estimate $$2.50 Consensus Rating Strong Buy Average Move 2.07% AstraZeneca's Monday Morning Call...

AZN : 169.64 (-0.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK , July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised...

AZN : 169.64 (-0.99%)
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or “the Company”)...

AZN : 169.64 (-0.99%)
3 Gold-Rated Schwab ETFs to Buy

When it comes to major ETF providers, Schwab might not be first to mind, but they offer up several solid, low-cost products that investors can build around.

NVDA : 200.75 (+2.93%)
GOOG : 356.65 (+6.88%)
GOOGL : 356.13 (+6.73%)
SCHO : 24.10 (-0.04%)
AAPL : 308.91 (-7.35%)
AZN : 169.64 (-0.99%)
SCHX : 29.44 (+0.65%)
SCHF : 27.43 (-0.58%)
HSBC : 106.42 (-0.63%)
NSRGY : 99.9500 (-2.42%)
AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky

AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are examining whether the losses tied to this collapse may be recoverable.

AZN : 169.64 (-0.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised...

AZN : 169.64 (-0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 173.07
2nd Resistance Point 171.91
1st Resistance Point 170.77
Last Price 169.64
1st Support Level 168.47
2nd Support Level 167.31
3rd Support Level 166.17

See More

52-Week High 212.71
Fibonacci 61.8% 187.15
Fibonacci 50% 179.25
Fibonacci 38.2% 171.35
Last Price 169.64
52-Week Low 145.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.